- Home
- CNTB vs TLSA Comparison
CNTB vs TLSA Comparison
Compare CNTB & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- TLSA
- Stock Information
- Founded
- CNTB 2012
- TLSA 2013
- Country
- CNTB United States
- TLSA United Kingdom
- Employees
- CNTB N/A
- TLSA N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- TLSA Health Care
- Exchange
- CNTB Nasdaq
- TLSA Nasdaq
- Market Cap
- CNTB 68.5M
- TLSA 87.8M
- IPO Year
- CNTB 2021
- TLSA 2000
- Fundamental
- Price
- CNTB $1.17
- TLSA $1.20
- Analyst Decision
- CNTB Strong Buy
- TLSA
- Analyst Count
- CNTB 1
- TLSA 0
- Target Price
- CNTB $8.00
- TLSA N/A
- AVG Volume (30 Days)
- CNTB 24.6K
- TLSA 145.8K
- Earning Date
- CNTB 09-05-2024
- TLSA 05-10-2024
- Dividend Yield
- CNTB N/A
- TLSA N/A
- EPS Growth
- CNTB N/A
- TLSA N/A
- EPS
- CNTB N/A
- TLSA N/A
- Revenue
- CNTB $24,116,000.00
- TLSA N/A
- Revenue This Year
- CNTB N/A
- TLSA N/A
- Revenue Next Year
- CNTB $63.90
- TLSA N/A
- P/E Ratio
- CNTB N/A
- TLSA N/A
- Revenue Growth
- CNTB N/A
- TLSA N/A
- 52 Week Low
- CNTB $0.68
- TLSA $0.41
- 52 Week High
- CNTB $2.84
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- CNTB 44.02
- TLSA 65.44
- Support Level
- CNTB $1.18
- TLSA $0.83
- Resistance Level
- CNTB $1.26
- TLSA $0.92
- Average True Range (ATR)
- CNTB 0.07
- TLSA 0.09
- MACD
- CNTB -0.01
- TLSA 0.03
- Stochastic Oscillator
- CNTB 13.59
- TLSA 84.52
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.